or pharmaceutically acceptable salts thereof, wherein

R^1, R^2 and R^3 are the same or different and are H, C_{1-6} alkyl (optionally phenyl substituted), C_{3-5} alkenyl or alkynyl or C_{3-10} cycloalkyl, or where R^3 is as above and R^1 and R^2 are cyclized with the attached N atom to form pyrrolidinyl, piperidinyl, morpholinyl, 4-methylpiperazinyl or imidazolyl groups;

X is H, F, Cl, Br, I, OH, C_{1-6} alkyl or alkoxy, CN, carboxamide, carboxyl or (C_{1-6} alkyl)carbonyl;

A is CH, CH_2, CHF, CHCl, CHBr, CHI, $CHCH_3$, C=O, C=S, $CSCH_3$, C=NH, CNH_2, $CNHCH_3$, $CNHCOOCH_3$, CNHCN, SO_2 or N;

B is CH, CH_2, CHF, CHCl, CHBr, CHI, C=O, N, NH or NCH_3, and n is 0 or 1; and

D is CH, CH_2, CHF, CHCl, CHBr, CHI, C=O, O, N, NH or NCH_3;

with various provisos indicated therein. WO 00/40226 further contemplates prescription of the drug (*R*)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-*ij*]-quinolin-2(1H)-one (*Z*)-2-butenedioate (1:1) to male and female subjects at a dose of 1-3 mg, to be taken 0.5-1 h before engaging in sexual activity, and indicates that at such a dose and timing of administration the drug is therapeutically effective. No information is provided as to the specific nature of dosage form.

IN THE CLAIMS

Please cancel without prejudice Claims 10–15 and 26–31.

Please amend Claims 1, 16–23 and 32–38 as follows.

1. (Amended) A pharmaceutical dosage form comprising (a) at least one agent effective in treatment of sexual dysfunction having a molecular weight, excluding counterions, not greater than 250, in a therapeutically or sexual-stimulatorily effective total amount, and (b) at least one pharmaceutically acceptable excipient; the dosage form being an oral dosage form selected from the group consisting of fast-melt formulations, breath-freshening pastilles, chewing gums, sublingual tablets, mucoadhesive films and oral strips, and having acceptable organoleptic properties.

16. (Amended) The dosage form of Claim 1 that dissolves in the mouth without need for drinking water or other fluid.

17. (Amended) The dosage form of Claim 1 that is a breath-freshening pastille.

18. (Amended) The dosage form of Claim 1 that is a chewing gum.

19. (Amended) The dosage form of Claim 1 that is a sublingual tablet.

20. (Amended) The dosage form of Claim 1 that is a mucoadhesive film.

A3

21. (Amended) The dosage form of Claim 1 that is an oral strip.

22. (Amended) The dosage form of Claim 1 that is an oral fast-melt tablet.

23. (Amended) A pharmaceutical dosage form comprising (a) a therapeutically or sexual-stimulatorily effective amount of about 0.1 mg to about 10 mg per dose of a therapeutic agent that comprises at least one compound of formula



or a pharmaceutically acceptable water-soluble salt thereof, said compound or salt thereof being water-soluble, wherein

R^1, R^2 and R^3 are the same or different and are H, C_{1-6} alkyl (optionally phenyl substituted), C_{3-5} alkenyl or alkynyl or C_{3-10} cycloalkyl, or where R^3 is as above and R^1 and R^2 are cyclized with the attached N atom to form pyrrolidinyl, piperidinyl, morpholinyl, 4-methylpiperazinyl or imidazolyl groups;

X is H, F, Cl, Br, I, OH, C_{1-6} alkyl or alkoxy, CN, carboxamide, carboxyl or (C_{1-6} alkyl)carbonyl;

A is CH, CH_2, CHF, CHCl, CHBr, CHI, $CHCH_3$, C=O, C=S, $CSCH_3$, C=NH, CNH_2, $CNHCH_3$, $CNHCOOCH_3$, CNHCN, SO_2 or N;

B is CH, CH_2, CHF, CHCl, CHBr, CHI, C=O, N, NH or NCH_3, and n is 0 or 1; and

D is CH, CH_2, CHF, CHCl, CHBr, CHI, C=O, O, N, NH or NCH_3;

and (b) one or more pharmaceutically acceptable excipients; the dosage form being an oral dosage form selected from the group consisting of fast-melt formulations, breath-freshening pastilles, chewing gums, sublingual tablets, mucoadhesive films and oral strips, and having acceptable organoleptic